CHF Solutions (CHFS) Lowered to “Sell” at Zacks Investment Research

CHF Solutions (NASDAQ:CHFS) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a research report issued to clients and investors on Friday, Zacks.com reports.

According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “

Separately, ValuEngine upgraded shares of CHF Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th.

NASDAQ CHFS traded down $0.12 on Friday, hitting $3.68. 41,464 shares of the company were exchanged, compared to its average volume of 161,691. The company has a market cap of $2.43 million, a price-to-earnings ratio of -0.09 and a beta of 2.65. The company has a quick ratio of 2.28, a current ratio of 5.86 and a debt-to-equity ratio of 0.03. CHF Solutions has a 1-year low of $3.15 and a 1-year high of $44.10.

CHF Solutions (NASDAQ:CHFS) last released its earnings results on Tuesday, May 7th. The company reported ($11.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.42) by ($10.05). CHF Solutions had a negative net margin of 336.26% and a negative return on equity of 188.60%. The business had revenue of $1.22 million for the quarter. On average, equities analysts expect that CHF Solutions will post -5.53 earnings per share for the current year.

In other CHF Solutions news, CEO John L. Erb bought 9,523 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were bought at an average cost of $5.25 per share, for a total transaction of $49,995.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 3.50% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of CHF Solutions in the 1st quarter valued at about $58,000. Vanguard Group Inc bought a new stake in shares of CHF Solutions in the 3rd quarter valued at about $39,000. Renaissance Technologies LLC bought a new stake in shares of CHF Solutions in the 1st quarter valued at about $218,000. Finally, Perkins Capital Management Inc. bought a new stake in shares of CHF Solutions in the 1st quarter valued at about $470,000. 84.39% of the stock is owned by institutional investors.

About CHF Solutions

CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Featured Article: Systematic Risk and Investors

Get a free copy of the Zacks research report on CHF Solutions (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.